Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Trial Drug: Lenvatinib

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with pembrolizumab, with or without chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.

Trial Drug: Lenvatinib

A Study to Evaluate Pembrolizumab in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein / Programmed Cell Death Ligand 1 Treatment

April 4, 2023

By Tyler Kalist

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with pembrolizumab, with or without chemotherapy, for the treatment of participants

A Study of Combination Therapies With Pembrolizumab in Participants With Advanced Esophageal Cancer

September 1, 2022

By Tyler Kalist

This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors

March 10, 2022

By Tyler Kalist

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors.

Safety and Efficacy Study of Pembrolizumab in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy

March 10, 2022

By Support_Clique

This study is a rolling arm study of pembrolizumab in combination with investigational agents in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors

March 10, 2022

By Support_Clique

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC),

Efficacy and Safety of Pembrolizumab Plus Lenvatinib Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma

March 10, 2022

By Tyler Kalist

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer

March 10, 2022

By Support_Clique

The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment

A Study of Pembrolizumab in Combination With Belzutifan and Lenvatinib , or Pembrolizumab/Quavonlimab in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma

March 10, 2022

By Support_Clique

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

March 10, 2022

By Support_Clique

The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting. No hypothesis

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis

March 10, 2022

By Support_Clique

Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

Posts navigation

Older posts
logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility